soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine SOUL: Oral Semaglutide Cuts CV

People with type 2 diabetes who were prescribed a GLP-1 receptor agonist, insulin or metformin and had no history of an obesity-associated cancer from March 2005 to November 2018 were included (mean age, 59.8 years

Transdermal bioavailability for these specific compounds has not been independently verified in published research

Hims & Hers had also planned to sell a compounded version of Novo Nordisk's oral semaglutide pill, but pulled the medication from its site only days after launch, following the Food and Drug Administration's announcement that it would crack down on compounded GLP-1 medications

Benefits of Taking Ozempic and Metformin Together Combining Ozempic and metformin can offer several benefits for individuals with type 2 diabetes